- Home
- XTNT vs CUE Comparison
XTNT vs CUE Comparison
Compare XTNT & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XTNT
- CUE
- Stock Information
- Founded
- XTNT N/A
- CUE 2014
- Country
- XTNT United States
- CUE United States
- Employees
- XTNT N/A
- CUE N/A
- Industry
- XTNT Biotechnology: Biological Products (No Diagnostic Substances)
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- XTNT Health Care
- CUE Health Care
- Exchange
- XTNT Nasdaq
- CUE Nasdaq
- Market Cap
- XTNT 60.9M
- CUE 60.6M
- IPO Year
- XTNT N/A
- CUE 2018
- Fundamental
- Price
- XTNT $0.45
- CUE $0.84
- Analyst Decision
- XTNT Strong Buy
- CUE Strong Buy
- Analyst Count
- XTNT 1
- CUE 3
- Target Price
- XTNT $3.00
- CUE $3.00
- AVG Volume (30 Days)
- XTNT 66.0K
- CUE 220.7K
- Earning Date
- XTNT 05-14-2025
- CUE 05-08-2025
- Dividend Yield
- XTNT N/A
- CUE N/A
- EPS Growth
- XTNT N/A
- CUE N/A
- EPS
- XTNT N/A
- CUE N/A
- Revenue
- XTNT $117,267,000.00
- CUE $9,287,000.00
- Revenue This Year
- XTNT $15.56
- CUE N/A
- Revenue Next Year
- XTNT $22.39
- CUE $4.77
- P/E Ratio
- XTNT N/A
- CUE N/A
- Revenue Growth
- XTNT 28.44
- CUE 69.16
- 52 Week Low
- XTNT $0.33
- CUE $0.45
- 52 Week High
- XTNT $0.97
- CUE $2.26
- Technical
- Relative Strength Index (RSI)
- XTNT 49.25
- CUE 48.41
- Support Level
- XTNT $0.34
- CUE $0.74
- Resistance Level
- XTNT $0.43
- CUE $0.80
- Average True Range (ATR)
- XTNT 0.05
- CUE 0.09
- MACD
- XTNT 0.01
- CUE 0.02
- Stochastic Oscillator
- XTNT 68.75
- CUE 83.49
About XTNT Xtant Medical Holdings Inc.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.